AdvisorShares Trust holds 203,564 Class B shares in Quantum Biopharma (QNTM)

Rhea-AI Filing Summary

Quantum Biopharma Ltd. reports a Schedule 13G filing showing AdvisorShares Trust beneficially owns 203,564 Class B Subordinate Voting Shares, representing 5.33% of that class.

The filing states AdvisorShares Trust holds sole voting and dispositive power over 203,564 shares. The disclosure is signed by the fund's Chief Compliance Officer on 07/08/2026.

Insights

Institutional Ownership Analyst

AdvisorShares Trust reports a 5.33% stake in Quantum Biopharma (Class B).

The filing lists 203,564 shares beneficially owned with sole voting and dispositive power. This indicates a passive institutional holding disclosed via Schedule 13G rather than an active acquisition disclosure.

Timing and transactional details are not included; subsequent filings would show any changes in position.

Key Figures

Beneficially owned: 203,564 shares Percent of class: 5.33% Sole voting power: 203,564 shares +1 more

4 metrics

Beneficially owned 203,564 shares Class B Subordinate Voting Shares

Percent of class 5.33% Percent of Class B shares owned by AdvisorShares Trust

Sole voting power 203,564 shares Sole power to vote or direct the vote

Sole dispositive power 203,564 shares Sole power to dispose or direct the disposition

Key Terms

Schedule 13G, beneficially owned, sole dispositive power

3 terms

Schedule 13G regulatory

"Schedule 13G filing showing AdvisorShares Trust beneficially owns 203,564 shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: 203,564"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 203,564"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

What stake does AdvisorShares Trust report in QNTM?

AdvisorShares Trust reports beneficial ownership of 203,564 Class B shares, or 5.33% of the class. The Schedule 13G indicates sole voting and dispositive power over those shares, as disclosed in the filing signed on 07/08/2026.

What does Schedule 13G mean for QNTM investors?

Schedule 13G is a passive investor disclosure for holders above certain thresholds. It shows AdvisorShares Trust reported a 5.33% passive stake in Class B shares, not an active control filing; it does not by itself indicate transactions or intent to influence management.

Who signed the 13G for AdvisorShares Trust in the QNTM filing?

The filing is signed by Stefanie Little, Chief Compliance Officer. The signature block shows the date 07/08/2026 and lists AdvisorShares Trust's Delaware citizenship and Bethesda, Maryland address.

Does the filing show voting or sale restrictions for QNTM shares?

The filing states AdvisorShares Trust has sole voting and sole dispositive power over 203,564 shares. It does not state any voting restrictions, sale plans, or whether shares were acquired on a particular date; transaction timing is not disclosed in the excerpt.

How significant is a 5.33% Class B stake in QNTM?

The Schedule 13G reports 5.33% ownership of Class B shares via 203,564 shares. The filing provides that percentage as the holder's share of that class; broader implications depend on total outstanding Class B shares, which are not provided in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/08/2026 - 05:21 PM Accepted by SEC EDGAR 07/08/2026 - 05:21 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quantum Biopharma Ltd.

(Name of Issuer)

Class B Subordinate Voting Shares, no par value

(Title of Class of Securities)

74764Y205

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74764Y205

1

Names of Reporting Persons

AdvisorShares Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 203,564.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 203,564.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

203,564.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.33 %

12

Type of Reporting Person (See Instructions)

IV

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 1 Adelaide Street East, Suite 801, Toronto, Ontario, Canada, M5C 2V9
Item 2.
(a)	Name of person filing: AdvisorShares Trust
(b)	Address or principal business office or, if none, residence: 4800 Montgomery Lane, Suite 150 Bethesda, Maryland 20814
(c)	Citizenship: Delaware
(d)	Title of class of securities: Class B Subordinate Voting Shares, no par value
(e)	CUSIP Number(s): 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 203,564
(b)	Percent of class: 5.33 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 203,564
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 203,564
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AdvisorShares Trust

Signature:	/s/ Stefanie Little
Name/Title:	Stefanie Little - Chief Compliance Officer
Date:	07/08/2026